Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin IV to Oral Switch in Japanese PID
NCT00871494Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azithromycin in pelvic inflammatory disease (PID), sponsored by Pfizer. Primary endpoint: Response Rate (Clinical Response, Data Review Committee Assessment) at Day 29. Started May 2009; status: completed.
02
Drugs
azithromycin
03
Conditions
pelvic inflammatory disease (PID)
Beyond the preview
Go deeper on NCT00871494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871494.